Comparison of Cisplatin and Lobaplatin in Intraperitoneal Perfusion Chemotherapy for Advanced Ovarian Cancer with Ascites

doi:10.3969/j.issn.1004-5775.2014.06.009

Abstract：Objective To evaluate efficacy and toxicity of cisplatin and lobaplatin in intraperitoneal perfusion chemotherapy for ad -vanced ovarian cancer with ascites .Methods Retrospective analysis was used to analyze the clinical materials of 36 cases about postopera-tive advanced ovarian cancer in Oncology Department of the People′s Hospital, Province Guizhou from January 2011 to December 2012, with 16 cases in cisplatin group(A group) and 20 cases in lobaplatin group(B group).Docetaxel chemotherapy was used on all the patients during intraperitoneal perfusion .Results There was no significant difference in CA 125 between A group and B group in first pre and post chemotherapy (P>0.05).There was no statistical significance between two groups after the second ,third and fourth cycle chemotherapy (P>0.05).But for the patients with gross residual disease ,after the first or second cycle chemotherapy , CA125 levels in A group were lower than that in B group (P<0.05).There were no statistical significance between two groups in the toxicities of hemoglobin , lower white blood cell, digestive disturbance and liver function damage;but A group were higher than that in B group in platelet decrease and renal function damage.Conclusion Intraperitoneal perfusion chemotherapy with cisplatin or lobaplatin is efficient and suitable for the advanced ovarian cancer with ascites after optimally cytoreductive surgery ,but cisplatin lowered recent CA 125 level will get sooner result than lobaplatin for those with gross residual disease .